Kaliumchlorid/Glucose B. Braun

Potassium chloride, the active ingredient in Kaliumchlorid/Glucose B. Braun, is an electrolyte solution presented as an injectable solution for intravenous use. It is used to correct low potassium levels and to provide glucose for energy and osmotic balance during infusion therapy.

GNH USA supplies Kaliumchlorid/Glucose B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Kaliumchlorid/Glucose B. Braun is used in electrolyte and carbohydrate replacement therapy for several clinical conditions.

Hypokalemia: restores potassium levels to prevent cardiac and muscular complications. Potassium replacement therapy: maintains electrolyte balance during prolonged IV treatment. Hypoglycemia: supplies glucose to raise blood sugar during acute episodes. Energy supplementation during IV therapy: provides carbohydrate substrate for metabolic needs.

Kaliumchlorid/Glucose B. Braun may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or irritation - Mild nausea or vomiting - Transient hyperglycemia - Mild hyperkalemia

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia - Anaphylactic reaction or severe hypersensitivity - Local tissue necrosis if extravasation occurs

When using Kaliumchlorid/Glucose B. Braun, clinicians should consider patient‑specific factors and monitor relevant parameters.

Renal impairment: monitor serum potassium and adjust infusion rate. Cardiac disease: avoid rapid potassium administration. Diabetes mellitus: monitor blood glucose closely. Concomitant potassium‑sparing diuretics: risk of hyperkalemia. Pregnancy and lactation: use only if clearly needed. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kaliumchlorid/Glucose B. Braun can interact with other medications that affect potassium or glucose balance.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may increase serum potassium. - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalemia. - Insulin therapy: concurrent high glucose may affect glycaemic control.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Digitalis glycosides: hyperkalemia can increase toxicity. - IV fluids containing potassium: cumulative potassium load.